关键信息
-
基因名
CD300LB
-
简介
The CD300LF protein, also known as DEC-205/CD205, directs antigens to the antigen-processing compartment. It inhibits myeloid cells and mast cells and promotes phagocytosis of apoptotic cells. CD300LF Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD300LF protein, expressed by HEK293 , with C-mFc labeled tag.
- 应用
-
别名
CMRF35-like molecule 1; CLM-1; CD300 antigen-like family member F; CD300f
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6SJQ7
-
表达区间
E20-S193
-
蛋白长度
Extracellular Domain
-
分子量
45.3 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CD300LB, a member of the CD300 family of immunoglobulin-like receptors, has gained increasing attention in immunological research due to its role in modulating immune responses. This receptor is primarily expressed on various immune cells, including myeloid lineage cells, where it influences cell activation, cytokine production, and phagocytic activity. Research indicates that CD300LB may act as a negative regulator of immune responses, particularly in the context of inflammation and autoimmune diseases. Understanding the signaling pathways and interactions of CD300LB with ligands can provide insights into its potential roles in maintaining immune homeostasis and preventing excessive immune activation. Furthermore, the exploration of CD300LB as a therapeutic target might open new avenues for treating conditions characterized by immune dysregulation, such as allergies and chronic inflammatory diseases. The generation of recombinant CD300LB proteins allows for detailed studies on its structure-function relationships and interactions with other molecules, advancing our knowledge of immune regulation mechanisms. Through such investigations, scientists aim to elucidate the therapeutic potential of modulating CD300LB activity in various clinical settings, highlighting its significance in both fundamental immunology and translational medicine.
